The antiproliferative effects of erlotinib, arising from cell-cycle arrest [30], might render tumor cells less sensitive to cytotoxic agents, as suggested by recent preclinical studies of combinations of EGFR TKIs with chemotherapy [31], [32]. The gene discussed is EGFR; the disease is neoplasm.